Cargando…

Co-crystals, Salts or Mixtures of Both? The Case of Tenofovir Alafenamide Fumarates

Tenofovir alafenamide fumarate (TAF) is the newest prodrug of tenofovir that constitutes several drug products used for the treatment of HIV/AIDS. Although the solid-state properties of its predecessor tenofovir disoproxil fumarate have been investigated and described in the literature, there are no...

Descripción completa

Detalles Bibliográficos
Autores principales: Lengauer, Hannes, Makuc, Damjan, Šterk, Damjan, Perdih, Franc, Pichler, Arthur, Trdan Lušin, Tina, Plavec, Janez, Časar, Zdenko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7238255/
https://www.ncbi.nlm.nih.gov/pubmed/32290280
http://dx.doi.org/10.3390/pharmaceutics12040342
_version_ 1783536503949885440
author Lengauer, Hannes
Makuc, Damjan
Šterk, Damjan
Perdih, Franc
Pichler, Arthur
Trdan Lušin, Tina
Plavec, Janez
Časar, Zdenko
author_facet Lengauer, Hannes
Makuc, Damjan
Šterk, Damjan
Perdih, Franc
Pichler, Arthur
Trdan Lušin, Tina
Plavec, Janez
Časar, Zdenko
author_sort Lengauer, Hannes
collection PubMed
description Tenofovir alafenamide fumarate (TAF) is the newest prodrug of tenofovir that constitutes several drug products used for the treatment of HIV/AIDS. Although the solid-state properties of its predecessor tenofovir disoproxil fumarate have been investigated and described in the literature, there are no data in the scientific literature on the solid state properties of TAF. In our report, we describe the preparation of two novel polymorphs II and III of tenofovir alafenamide monofumarate (TA MF2 and TA MF3). The solid-state structure of these compounds was investigated in parallel to the previously known tenofovir alafenamide monofumarate form I (TA MF1) and tenofovir alafenamide hemifumarate (TA HF). Interestingly, the single-crystal X-ray diffraction of TA HF revealed that this derivative exists as a co-crystal form. In addition, we prepared a crystalline tenofovir alafenamide free base (TA) and its hydrochloride salt (TA HCl), which enabled us to determine the structure of TA MF derivatives using (15)N-ssNMR ((15)N-solid state nuclear magnetic resonance). Surprisingly, we observed that TA MF1 exists as a mixed ionization state complex or pure salt, while TA MF2 and TA MF3 can be obtained as pure co-crystal forms.
format Online
Article
Text
id pubmed-7238255
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-72382552020-06-02 Co-crystals, Salts or Mixtures of Both? The Case of Tenofovir Alafenamide Fumarates Lengauer, Hannes Makuc, Damjan Šterk, Damjan Perdih, Franc Pichler, Arthur Trdan Lušin, Tina Plavec, Janez Časar, Zdenko Pharmaceutics Article Tenofovir alafenamide fumarate (TAF) is the newest prodrug of tenofovir that constitutes several drug products used for the treatment of HIV/AIDS. Although the solid-state properties of its predecessor tenofovir disoproxil fumarate have been investigated and described in the literature, there are no data in the scientific literature on the solid state properties of TAF. In our report, we describe the preparation of two novel polymorphs II and III of tenofovir alafenamide monofumarate (TA MF2 and TA MF3). The solid-state structure of these compounds was investigated in parallel to the previously known tenofovir alafenamide monofumarate form I (TA MF1) and tenofovir alafenamide hemifumarate (TA HF). Interestingly, the single-crystal X-ray diffraction of TA HF revealed that this derivative exists as a co-crystal form. In addition, we prepared a crystalline tenofovir alafenamide free base (TA) and its hydrochloride salt (TA HCl), which enabled us to determine the structure of TA MF derivatives using (15)N-ssNMR ((15)N-solid state nuclear magnetic resonance). Surprisingly, we observed that TA MF1 exists as a mixed ionization state complex or pure salt, while TA MF2 and TA MF3 can be obtained as pure co-crystal forms. MDPI 2020-04-10 /pmc/articles/PMC7238255/ /pubmed/32290280 http://dx.doi.org/10.3390/pharmaceutics12040342 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lengauer, Hannes
Makuc, Damjan
Šterk, Damjan
Perdih, Franc
Pichler, Arthur
Trdan Lušin, Tina
Plavec, Janez
Časar, Zdenko
Co-crystals, Salts or Mixtures of Both? The Case of Tenofovir Alafenamide Fumarates
title Co-crystals, Salts or Mixtures of Both? The Case of Tenofovir Alafenamide Fumarates
title_full Co-crystals, Salts or Mixtures of Both? The Case of Tenofovir Alafenamide Fumarates
title_fullStr Co-crystals, Salts or Mixtures of Both? The Case of Tenofovir Alafenamide Fumarates
title_full_unstemmed Co-crystals, Salts or Mixtures of Both? The Case of Tenofovir Alafenamide Fumarates
title_short Co-crystals, Salts or Mixtures of Both? The Case of Tenofovir Alafenamide Fumarates
title_sort co-crystals, salts or mixtures of both? the case of tenofovir alafenamide fumarates
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7238255/
https://www.ncbi.nlm.nih.gov/pubmed/32290280
http://dx.doi.org/10.3390/pharmaceutics12040342
work_keys_str_mv AT lengauerhannes cocrystalssaltsormixturesofboththecaseoftenofoviralafenamidefumarates
AT makucdamjan cocrystalssaltsormixturesofboththecaseoftenofoviralafenamidefumarates
AT sterkdamjan cocrystalssaltsormixturesofboththecaseoftenofoviralafenamidefumarates
AT perdihfranc cocrystalssaltsormixturesofboththecaseoftenofoviralafenamidefumarates
AT pichlerarthur cocrystalssaltsormixturesofboththecaseoftenofoviralafenamidefumarates
AT trdanlusintina cocrystalssaltsormixturesofboththecaseoftenofoviralafenamidefumarates
AT plavecjanez cocrystalssaltsormixturesofboththecaseoftenofoviralafenamidefumarates
AT casarzdenko cocrystalssaltsormixturesofboththecaseoftenofoviralafenamidefumarates